PellePharm announced its launch today, with financing from BridgeBio Pharma. The Menlo Park, Calif.-based company is developing a topical gel to treat basal cell carcinoma, including the tumors that result from Gorlin syndrome.
The company’s topical inhibitor compound, patidegib, acts on the hedgehog pathway – a signaling pathway that transmits cellular information for adult tissue maintenance. Abnormal hedgehog signaling has been correlated with a number of cancers including basal cell carcinoma. PellePharm is studying the topical formulation of patidegib in 2 phase II trials. A study evaluating the gel’s use in patients with Gorlin syndrome just completed enrollment, according to the company.
Get the full story at our sister site, Drug Delivery Business News.